RxDoctor Payments Data

Yvonne Kew, MD

Neurology · Houston, TXNPI 1871673137

Payments from drug & device makers

$2,063in general payments, 2019–2025

Across 57 payments — averaging $36.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GT Medical Technologies, Inc$354
  • Biogen$237
  • EMD Serono, Inc.$230
  • SK Life Science, Inc.$188
  • Lilly USA, LLC$136
  • Sanofi$125
  • plus $793 from 14 others

What the payments were for

  • Consulting fees$1507%
  • Food & beverage$1,88691%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,063 in reported general payments places this provider in the 45th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$342,298
Medicare patients
98
Services billed
10,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate26$33,674
Aimovig AutoinjectorErenumab-Aooe19$18,302
Emgality PenGalcanezumab-Gnlm11$17,632
FycompaPerampanel15$15,599
Lacosamide21$3,096
Aripiprazole82$2,884
Memantine Hcl98$1,970
Duloxetine Hcl50$1,938
Sertraline Hcl45$1,091
Clorazepate Dipotassium22$832
Levetiracetam37$730
Cyclobenzaprine Hcl19$685
Venlafaxine Hcl ErVenlafaxine Hcl22$562
Mirtazapine34$548
Gabapentin46$523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$188$33,67426 claims
Eisai Inc.Fycompa$65$15,59915 claims
Upsher-smith Laboratories LLCTopiramate$34$10715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →